We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -156.00 | -1.44% | 10,662.00 | 2,788,748 | 16:35:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10,658.00 | 10,662.00 | 10,838.00 | 10,598.00 | 10,702.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 54.07B | USD 7.04B | USD 4.5368 | 23.49 | 167.75B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:50:07 | O | 46 | 10,158.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/6/2025 | 11:45 | UK RNS | Niox Group PLC Holding(s) in Company |
| 13/6/2025 | 10:19 | ALNC |  AstraZeneca boosts China ties with up to USD5.3 billion partnership |
| 13/6/2025 | 09:30 | UK RNS | AstraZeneca PLC AstraZeneca enters into collaboration with CSPC |
| 12/6/2025 | 15:00 | UK RNS | AstraZeneca PLC Director/PDMR Shareholding |
| 06/6/2025 | 09:02 | ALNC | AstraZeneca's Calquence gets EU nod to treat adults with leukaemia |
| 06/6/2025 | 07:00 | UK RNS | AstraZeneca PLC Fixed-duration Calquence approved in EU for 1L CLL |
| 02/6/2025 | 15:05 | UK RNS | AstraZeneca PLC Block listing Interim Review |
| 02/6/2025 | 15:00 | UK RNS | AstraZeneca PLC Total Voting Rights |
| 02/6/2025 | 14:23 | ALNC | AstraZeneca says Enhertu slashes disease progression risk in cancer |
| 02/6/2025 | 06:45 | ALNC | AstraZeneca hails Imfinzi results on early stage gastric cancer |
Astrazeneca (AZN) Share Charts1 Year Astrazeneca Chart |
|
1 Month Astrazeneca Chart |
Intraday Astrazeneca Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/6/2025 | 20:10 | AstraZeneca | 6,316 |
| 25/4/2024 | 08:41 | Alzheimer's can be caught .... It's a transmissible disease | 126 |
| 02/11/2021 | 14:29 | ASTRAZENECA, MSD PROSTATE CANCER DRUG GETS CHINA GREEN LIGHT | 2 |
| 20/9/2021 | 15:45 | INDIA'S COVID DEATH RATE IS 278 PER 1 MILLION..UK'S IS 1876..THINK ABOUT IT | 1 |
| 15/9/2021 | 12:17 | Eu | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-06-17 17:59:34 | 10,158.00 | 46 | 4,672.68 | O |
| 2025-06-17 17:59:34 | 10,568.00 | 50 | 5,284.00 | O |
| 2025-06-17 17:59:34 | 10,148.00 | 56 | 5,682.88 | O |
| 2025-06-17 17:59:33 | 10,240.00 | 42 | 4,300.80 | O |
| 2025-06-17 17:59:33 | 10,070.00 | 44 | 4,430.80 | O |
| Top Posts |
|---|
Posted at 17/6/2025 09:20 by Astrazeneca Daily Update Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,818p.Astrazeneca currently has 1,550,657,962 shares in issue. The market capitalisation of Astrazeneca is £165,269,125,590. Astrazeneca has a price to earnings ratio (PE ratio) of 23.49. This morning AZN shares opened at 10,702p |
Posted at 16/6/2025 20:10 by 1jat We will find out in due course what the Trump edicts result in…..but the lawyers and accountants will find ways to mitigate them…More drugs will be discovered outside the US and will not be distributed in the US leading to poorer patient outcomes. US will have reduced R&D earnings. US may get modified drugs so price comparison fails. In the US, the price to the customer will be broken down into each entities fee, drug, pharmacy, prescription charge will be separated and the overall end user price will remain largely unchanged (although under pressure - a bit like UK financial services where commissions need to be disclosed). |
Posted at 27/5/2025 09:15 by geckotheglorious Equity edge: Why is AstraZeneca so cheap?Waverton UK equity research head explains why Trump’s bark may be worse than his bite for cheap AstraZeneca. The long-term prospects of UK drug giant AstraZeneca (GB:AZN) look the brightest they have in years, but its shares are also near their cheapest in a decade. Despite the angst evident from the shares’ valuation, Astra remains hugely popular with the world’s best portfolio managers tracked by Citywire resulting in it having a top AAA Elite Companies rating. We’ve caught up with Tineke Frikkee, head of UK equity research at wealth manager Waverton Investment Management, to find out why Astra is so cheap and whether it is justified. Triple Trump trouble Sentiment towards drug manufacturers has taken a triple hit from Trump. First it was tariffs, then Trump’s declaration the US should have ‘most-favoured But why are drug makers in Trump’s firing line? ‘Most novel new drugs are launched in the US first because it’s a big market and also because the FDA is just a really well-oiled machine. Trump then claims the US is paying for all the R&D and everyone else is piggybacking,’ said Frikkee. Trump has been trouble for AstraZeneca shares But as Tump’s bombast has begun to collide with reality in multiple areas, Frikkee thinks his administration&rsquo All talk? ‘First, people wondered how tariffs would work?’ she said. ‘It is clear that a lot of pharmaceutical companies actually make US medicine in the US. The companies made that obvious in their last results.’ Most-favoured-nation pricing, meanwhile, whereby the US government would pay the lowest international price for drugs, faces problems due to the idiosyncrasies of the US health system. ‘The US is unique in that there is a wholesale price that medicine gets sold at and there is a net price that the US government actually buys at. And there are third party distributors that take a cut. That doesn’t exist anywhere else in the world. ‘When they compare the wholesale price in a country with their net price, that can be quite easily legally disputed… which tends to take two to three years,’ she said. ‘And this is product by product, so this is going to be a big exercise. ‘It is also not straightforward because the most recent drugs don’t have another price because the US is their first market.’ Meanwhile, in her conversations with Astra and other drug companies, Frikkee is yet to detect signs of real disruption to the functioning of the drug approval process. Perhaps most fundamentally, she does not see the US as being the most convincing of victims. ‘The advantage of having all these patents filed in the US is the US receives patent tax, but Trump doesn’t talk about that,’ she said. ‘And I don’t think he wants headlines that US citizens are being denied novel drugs.’ Astra 2030 Developments in the US are a big issue for Astra given it makes just over two fifths of sales inthe country. But beyond these worries, its underlying business looks in great shape following an extensive period of restructuring and investment since the appointment of Pascal Soriot as chief executive in mid 2012. ‘Soriot decided that there was far more value that they could create internally and really revamped the research and development (R&D) processes to being much more commercial, said Frikkee. ‘That takes time, and it was from 2018 that they started to really deliver consistently.’ As well as reinvigorating sales growth, Astra has pushed into higher-margin specialist treatment areas for cancers and rare diseases, which has boosted overall profitability. The growth also means the company has more money to plough into its ‘R&D machine’, which Frikkee rates as the most effective of the big pharma players. The group’s target of doubling revenue to $80bn by the end of the decade rests of the success of this ‘R&D machine’ and the second half will be a big test of its effectiveness as a number of major trial results are due. The risk of disappointments is reduced thanks to Astra having few big-selling drugs coming off patent until after 2030 while the diversity of the group’s portfolio of medicines means patent maturities are well spread out. But if trial results are good in the second half of 2025 and Trump-related fears ease, Astra’s shares could richly reward their Elite backers’ show of faith. |
Posted at 13/5/2025 10:52 by geckotheglorious US drug prices artificially high for a variety of reasons.One of which is US consumers/taxpayers subsidise same drugs at cheaper prices for poor nations. A big change may soon be coming to the U.S. pharmaceutical market, where consumers pay exponentially more than any other country in the world. Due to the many players in the system, it has been hard to pin down an exact cause of the expenses or what to do about drug pricing, but there have been many attempts to change the status quo. The latest effort will come this morning, with many watching the developments, including Big Pharma and what it will mean for their shareholders. Announcement: "In the White House, at 9:00 A.M., I will be signing one of the most consequential Executive Orders in our Country’s history," President Trump wrote on Truth Social. "Prescription Drug and Pharmaceutical prices will be REDUCED, almost immediately, by 30% to 80%. They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World." Many have pointed to the U.S. market as the one that covers the research and development costs for much of the globe, especially given drug companies' ability to dictate their listing prices. In most other nations, the government buys the stock of medicine for a country, so it is able to negotiate lower rates or bulk discounts, and can walk away from a deal based on "affordability and value." That rarely happens in the U.S., whose market is based on "access and availability." Private insurers will agree to nearly every deal, but just charge more. Other differences: Direct-to-consumer marketing is allowed in the U.S. (bloating advertising expenses), while companies must make sure they keep prices inflated before patents expire and generics are released. Unlike other countries, there is also the existence of pharmacy benefit managers, referred to as "middlemen," who work for insurance companies and government agencies. PBMs attempt to bring down the cost of U.S. drugs by negotiating discounts and rebates, but they also take a percentage and have immense power over where a drug is placed on an insurer's formulary (tiers that classify how much a consumer vs. insurer has to pay for any given medicine). PBMs also won't release their "proprietary" rebate data publicly, which can influence costs, sales, and initial listing prices |
Posted at 12/5/2025 08:59 by wskill Not good AZN needs much higher pricing due to US courts awarding damages far beyond what is sensible and without proper science based evidence.Should this come into law there will no longer be a profitable market for anyone except USA owned pharma companies. Azn gets about 30% of revenue from the USA its the price that it sells at that counts and unfortunately its high in comparison to elsewhere in the world ,its not good for countries which cannot afford to pay more as the price they pay will rise to American price points. |
Posted at 06/5/2025 09:30 by undervaluedassets Tariffs should not be too bad ..Have huge manufacturing facilities in the US:- 17800 employees in the US. 17 research, development, manufacturing and commercial sites across the US. 9 billion doses of medicine produced in the US. In November 2024 AZN announced a 3.5 billion investment to expand in US manufacturing research and development capabilities in the US So in this crazy Trump-tariff world that we all find ourselves in AZN is well positioned. |
Posted at 28/11/2024 09:10 by wskill benralizumab first new treatment for Asthma and COPD for 50 years and injection every 4 to 8 weeks looks like a game changer to me .AZN share price is sure to fall today Edit . benralizumab/Fasenra looks to have been in phase 3 trials since 2013 why would it take so long ,or has there been some improvements made in benralizumab /Fasenra . cost seems a little high $5197 per ml It was approved by US and EU regulators in 2017 but just 7 years later they find that its by injection that it can stop severe asthma and COPD attacks 4 times better than the standard steroid treatment.Better late than never I would say. |
Posted at 14/11/2024 08:19 by m_night10 #POLX Polarean Imaging 1.6p about to break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025. 1.6p and gap to fill to 3.2p, so 100% rise just to fill the technical gap. ATH 100p. My target is recovery to 25p.Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv and big riser. DYOR, not advice. |
Posted at 12/11/2024 10:16 by fuji99 Agree Monty that China is the big hurdle for any positive share price movement regardless of the results and progress they make.The market hates uncertainty and these are questions that anyone can ask: What are the repercussions from China ? Is AZN going to be involved in Chinese courts ? Possible big fine if breaches are serious ? Any financial repercussion may hurt AZN numbers thus why the share price is "floating" at the moment. All these uncertainties will continue to weigh on the share price untill all is clarified once for all. |
Posted at 10/11/2024 00:10 by philanderer AstraZeneca has explaining to do after £50 billion value wipe outAt the start of September when its share price was at an all-time high and it was comfortably the UK’s largest company, AstraZeneca PLC (LSE:AZN) management might have been expecting a routine third-quarter update. Two months on however and £50 billion has been wiped from its value with growing questions over its pipeline and operation in China. Poor trial results and some questionable PR – putting out a three- sentence response to the China issue during the middle of Rachel Reeves’ Budget speech for example - have added to the unease. The trial disappointments surround its dato-DXd cancer drug and its fledgling move into the weight loss drug arena. In China, AstraZeneca has confirmed its president there Leon Wang is co-operating with the authorities as part of an ongoing investigation but has given no details, saying it will not comment on speculative media reports. Some City commentators have suggested that the pharma is not directly involved and the share price fall is exaggerated. ShoreCap, in a detailed look at the issue, added Astra could help alleviate investor concerns by providing clarity on its China business and reaffirming its growth prospects in the third quarter update. Whether it chooses to remains to be seen proactiveinvestors.c |
Posted at 05/11/2024 17:24 by philanderer Looking like China relatedRNS from the Company just out 05 November 2024 AZN share price movement As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China. If requested, we will fully cooperate with the Chinese authorities. We continue to deliver our life changing medicines to patients in China and our operations are ongoing. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
